Monopar TherapeuticsMNPR -1.76%35 Cyclically Adjusted PB Ratio is 14.35 as of Jul. 13, 2026. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 697 Biotechnology companies, Monopar Therapeutics ranks worse than 90.96% on this metric.
The historical rank and industry rank for Monopar Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
MNPR'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 14.59
Current: 14.59
During the past 10 years, Monopar Therapeutics's highest Cyclically Adjusted PB Ratio was 14.59. The lowest was 0.00. And the median was 0.00.
MNPR's Cyclically Adjusted PB Ratio is ranked worse than 90.96% of 697
companies
in the Biotechnology industry
Industry Median: 1.62
vs MNPR: 14.59
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Monopar Therapeutics's adjusted book value per share data of for the fiscal year that ended in Dec25 was $20.596. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $7.30 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Monopar Therapeutics (NAS:MNPR) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Monopar Therapeutics Cyclically Adjusted PB Ratio Related Terms
Monopar Therapeutics Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Monopar Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monopar Therapeutics Cyclically Adjusted PB Ratio Chart
MNPR vs MDXG, FTH, BBOT: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Monopar Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monopar Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Monopar Therapeutics's Cyclically Adjusted PB Ratio falls into.
Monopar Therapeutics Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 14.35 mean?
Monopar Therapeutics (MNPR) has a Cyclically Adjusted PB Ratio of 14.35 as of Jul. 13, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Monopar Therapeutics and its competitors. According to the industry distribution chart, Monopar Therapeutics ranks #634 out of 697 companies in the Biotechnology industry, placing it in the top 91%.
Is Monopar Therapeutics' Cyclically Adjusted PB Ratio too high?
Monopar Therapeutics' current Cyclically Adjusted PB Ratio is 14.35. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.62. Monopar Therapeutics' value of 14.35 is 785.8% above this industry median. Based on the distribution chart, Monopar Therapeutics ranks #634 out of 697 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Cyclically Adjusted PB Ratio compare to MDXG and FTH?
According to the Biotechnology industry distribution chart, Monopar Therapeutics ranks #634 out of 697 companies for Cyclically Adjusted PB Ratio. This places Monopar Therapeutics in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.62. Monopar Therapeutics' value of 14.35 is 785.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.62, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monopar Therapeutics's current Cyclically Adjusted PB Ratio of 14.35 is 785.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Monopar Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monopar Therapeutics's current Cyclically Adjusted PB Ratio is 14.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Cyclically Adjusted PB Ratio of 14.35. The current Cyclically Adjusted PB Ratio is 14.35 and 785.8% above the Biotechnology industry median of 1.62. Monopar Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Cyclically Adjusted PB Ratio is 14.35 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score
Get the complete analysis for MNPR
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNPR has been successfully added to your 
